GHD Reversal Trial: Follow Up Worksheet (6 months to 36+ months)

Follow up for the GHD reversal trial should take place at 6 monthly intervals until near final height is reached. It is expected that participants will reach near final height by 36 months post randomisation. However, if this does not occur, please contact the Trial Team at BCTU for further guidance on additional follow up.

Trial Number ☐☐☐☐ | Participant DOB *e.g. JAN-2017* M M M Y Y Y Y

Site name _____

Section 1 - Visit Details

Assessment Date *e.g. 31-JAN-2017* D D - M M M - Y Y Y Y

Assessment point (months) *Please tick one*

◯ 6 ◯ 12 ◯ 18 ◯ 24 ◯ 30 ◯ 36 ◯ 42 ◯ 48 ◯ 54 ◯ 60

Additional visits after 36 months should only occur if near final height has not been reached. Please contact the GHD Reversal Trial team at BCTU for further information.

Section 2 - Clinical Details

Height (mean) *See Protocol V4.0, Section 10.5 for clarification of measurement procedure.* ___ ___ ___ . ___ cm

Weight ___ ___ ___ . ___ kg

Annualised growth velocity *Please use annualised growth velocity calculator on trial website to calculate* ___ ___ . ___ ___ cm/year

If annualised growth velocity is <2cm/year, a hand X-ray should be carried out and Section 3 completed.

Tanner stage (P) *Please tick one*

◯ Stage 2 ◯ Stage 3 ◯ Stage 4 ◯ Stage 5

Tanner stage: testes volume (ml) *Please complete for MALE participants. Please tick one*

◯ 6 ◯ 8 ◯ 10 ◯ 12 ◯ 15 ◯ 20 ◯ =>25

Tanner stage: breast development (B) *Please complete for FEMALE participants. Please tick one.*

◯ Stage 2 ◯ Stage 3 ◯ Stage 4 ◯ Stage 5

Section 3 - Bone-related Data

To be completed at near final height if annualised growth velocity is <2cm/year.

It is recommended that the X-ray is performed on the participant's non-dominant hand where possible, and the same hand should be X-rayed throughout the trial. Bone Xpert X-ray analysis is conducted at Great Ormond Street Hospital (UK participants) and Kepler Universitätsklinikum (Austrian participants). Results are sent to the participant's site and should be entered onto the trial database by site staff. Please see section 10.4 of the protocol for further details of the hand X-ray process.

Has a hand X-ray been performed? *Please tick one* ◯ Yes ◯ No

Specify hand used for X-ray *Please tick one* ◯ Dominant ◯ Non-dominant

Date of X-ray *e.g. 31-JAN-2017* D D - M M M - Y Y Y Y

Bone age ___ ___ . ___ ___ years

Bone Health Index ___ . ___ ___

Was epiphyseal fusion present on hand x-ray? *Please tick one* ◯ Present ◯ Absent

If epiphyseal fusion is present on hand x-ray, please complete Near Final Height Form. If absent, another hand x-ray should be carried out in 6 months, and the Follow Up form completed again.

Section 4 - Growth Hormone Monitoring

To be completed at 6, 12, 24, 36 months, and Near Final Height (if reached at other time point), for ALL participants

Was the serum IGF-1 concentration measured at this assessment? *Please tick one* ◯ Yes ◯ No

Serum IGF-1 assay used *Please tick one*

◯ IDS iSYS ◯ Immulite 2000 Family
◯ Roche Elecsys ◯ Siemens Immulite
◯ Diasorin Liaison ® XL ◯ Other

If Other, please specify _____

Date sample taken *e.g. 31-JAN-2017* D D - M M M - Y Y Y Y

Serum IGF-1 concentration ___ ___ ___ . ___

Serum IGF-1 unit *Please tick one* ◯ nmol/L ◯ µg/L ◯ ng/ml ◯ Other

If other Serum IGF-1 unit, please specify _____

Was the serum IGF-1 within the normal reference range for sex and age? *Please tick one* ◯ Yes ◯ No

To be completed at 6 month assessment: for participants randomised to the Experimental arm (GH withdrawal) ONLY

If suboptimal growth is noticed at the 6 month assessment, and serum IGF-1 concentration falls below the normal reference range, a GH stimulation test should be conducted.

Has a GH stimulation test been conducted? ◯ Yes ◯ No

Date sample taken *e.g. 31-JAN-2017* D D - M M M - Y Y Y Y

Peak GH ___ ___ . ___ µg/L

Test used *Please tick one* ◯ Insulin tolerance test ◯ Arginine ◯ Glucagon ◯ Other

If 'Other' test has been used, please specify _____

Was the test sex steroid primed? *Please tick one* ◯ Yes ◯ No

Please note: for the purposes of the GHD Reversal Trial, insulin tolerance test, glucagon and arginine are stipulated as the required GH stimulation tests within the protocol.

Section 5 - Growth Hormone Therapy Treatment Compliance

For ALL participants: Has the participant taken any growth hormone therapy since last trial assessment? *Please tick one* ◯ Yes ◯ No

Please record details of all growth hormone therapy taken since last trial assessment on the GHD Reversal Trial Medication Form.

Please ask participants/ parents randomised to **continue therapy** whether any doses of growth hormone have been missed since last trial assessment. Based on their response, please estimate adherence using the percentage parameters below.

For participants randomised to the **Control** arm (continuing GH) ONLY: Estimated adherence *Please tick one*

◯ High (≥85%) ◯ Intermediate (>56-84%) ◯ Low (≤56%)

Section 6 - Concomitant Medication

Is the participant taking any other endocrine medication (including both new prescriptions since last assessment, and ongoing medicines at the time of the assessment)? *Please tick one* ◯ Yes ◯ No

Has the participant stopped any endocrine medication since their last assessment *Please tick one* ◯ Yes ◯ No

Please record details of all endocrine medication on the GHD Reversal Trial Medication Form.

Section 7 - Adverse Events

Please document the presence of the targeted adverse events specified in the table below for ALL participants

Adverse Events		
	Present or absent	Fulfils criteria for SAE?
Lipoatrophy	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No
Headache	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No
Idiopathic intracranial hypertension	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No
Increased levels of fatigue	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No
Increased levels of weight gain*	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No
Abnormal lipid profile	◯ Present ◯ Absent ◯ Unknown	◯ Yes ◯ No

***Increased levels of weight gain defined as an increase of more than 2 centile lines, or change in weight SDS over 1 SD.**

An Adverse Event is defined as Serious if it meets one of the following criteria:

- ◯ Results in death
- ◯ Is life threatening
- ◯ Requires in-patient hospitalisation for more than 24 hours, or prolongation of an existing hospitalisation
- ◯ Results in persistent or significant disability or incapacity
- ◯ Results in a congenital anomaly or a birth defect
- ◯ Is otherwise considered medically significant by the Investigator

If any of the SAE criteria above are met for any patient in the trial please complete the GHD Reversal Trial SAE form. For further details, please see section 9 of the protocol.

Section 8 - Pregnancy screening- please complete for female participants ONLY

Is the participant pregnant? *Please tick one* ◯ Yes ◯ No

If the participant is pregnant, please complete the GHD Reversal Trial Pregnancy Notification Form.

Section 9 - Withdrawal

Is the participant/ parent willing to continue in the trial? *Please complete at each assessment*

◯ Yes ◯ No ◯ Not Applicable (end of follow up)

If the participant is NOT willing to continue in the trial, please complete the Trial Exit/ Change of Status Form.

Section 10 - Details of worksheet completion

Completed by *This person must be listed on the delegation log*

PI (or delegate) signature:

Date form completed *e.g. 31-JAN-2017* D D - M M M - Y Y Y Y

Thank you for completing the GHD Reversal Trial Follow Up Worksheet. Please enter all data onto the participant's electronic case report form:

https://www.trials.bham.ac.uk/GHD

In addition to the follow up form, please ensure the following are also completed at the time of assessment:

- GHD Reversal Trial Medication Form (all assessments)

-Child Health Utility-9D questionnaire (to be completed by the participant at all assessments)

-GHD Reversal Trial Healthcare Contacts Form (to be completed at the 6, 12, 24 and 36 month assessments)

-GHD Reversal Trial Near Final Height Form (to be completed when participant reaches near final height/ at the 36 month assessment)

Note: If a participant has NOT reached Near Final Height with epiphyseal fusion by the time of the 36 month assessment, please contact the GHD Reversal Trial team at BCTU for further guidance on the additional follow up required.